Skip to content

    Cancer Health Center

    Font Size

    FDA: Prostate Cancer Drugs Raise Diabetes, Heart Risk

    New Warnings for Eligard, Lupron, Trelstar, Viadur, Zoladex
    WebMD Health News
    Reviewed by Laura J. Martin, MD

    Oct. 20, 2010 -- A class of drugs used to treat advanced prostate cancer raises patients' risk of diabetes, heart disease, and stroke, the FDA today warned.

    The five drugs, gonadotropin-releasing hormone (GnRH) agonists, are approved for the treatment of advanced prostate cancer. They are:

    All of the drugs will stay on the market but will be required to carry new label warnings.

    The risk that the drugs will trigger diabetes or heart disease/stroke appear small, the FDA says. But recent studies suggest that doctors should monitor blood sugar levels and watch for signs of heart disease in men taking these drugs.

    Patients should not stop taking these drugs, but should discuss any concerns with their doctors.

    Before beginning treatment with any of these drugs, patients should tell their doctors whether they've ever had diabetes, heart disease, a heart attack, or a stroke. They should also report any history of high blood pressure, high cholesterol, or cigarette smoking.

    Today's FDA action follows the agency's announcement last May that it was reviewing safety concerns raised by new data on GnRH agonists.

    Today on WebMD

    man holding lung xray
    What you need to know.
    stem cells
    How they work for blood cancers.
    woman wearing pink ribbon
    Separate fact from fiction.
    Colorectal cancer cells
    Symptoms, screening tests, and more.
    Jennifer Goodman Linn self-portrait
    what is your cancer risk
    colorectal cancer treatment advances
    breast cancer overview slideshow
    prostate cancer overview
    lung cancer overview slideshow
    ovarian cancer overview slideshow
    Actor Michael Douglas